Drugs / MK0493
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00482196 | Jul 2005 → Mar 2006 | obesity disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00482638 | May → Oct 2004 | obesity disorder | Merck Sharp & Dohme LLC | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-0493 | “MK-0493 is a novel, potent, and selective agonist of the melanocortin receptor 4 (MC4R), one of the best-validated genetic targets and considered one of the most promising for...” PMID 19741604 ↗ Sep 2009 |
| Action | Activate | “selective agonist of the melanocortin receptor 4 (MC4R)” PMID 19741604 ↗ Sep 2009 |
| Target | MC4R | “selective agonist of the melanocortin receptor 4 (MC4R)” PMID 19741604 ↗ Sep 2009 |